<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="4219">
  <stage>Registered</stage>
  <submitdate>9/12/2013</submitdate>
  <approvaldate>9/12/2013</approvaldate>
  <nctid>NCT02017210</nctid>
  <trial_identification>
    <studytitle>Insulin-sensitive Obesity: Lessons From Longitudinal Data</studytitle>
    <scientifictitle>Insulin-sensitive Obesity: Prospective and Interventional Studies</scientifictitle>
    <utrn />
    <trialacronym>ISOS</trialacronym>
    <secondaryid>ISOS (SVH 13/143)</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Insulin Sensitivity/Resistance</healthcondition>
    <healthcondition>Obesity</healthcondition>
    <healthcondition>Weight Loss</healthcondition>
    <conditioncode>
      <conditioncode1>Diet and Nutrition</conditioncode1>
      <conditioncode2>Obesity</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Other metabolic disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Other interventions - Longitudinal study

Experimental: Longitudinal follow up - Participant's metabolic parameters are followed up after approximately 6 years.


Other interventions: Longitudinal study
Metabolic health, anthropometry, body fat distribution, liver lipid will be followed up in individuals previously studied at the Clinical Research Facility.

</interventions>
    <comparator />
    <control />
    <interventioncode>Other interventions interventions</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Change in insulin sensitivity - Insulin sensitivity will be assessed in this current follow up study. This will be compared to insulin sensitivity data collected in this study cohort approximately 6 years ago.</outcome>
      <timepoint>change in insulin sensitivity at follow up compared to 6 years ago</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Change in anthropometry (weight, height, BMI, waist and hip circumference)</outcome>
      <timepoint>Change at follow up compared to 6 years ago</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in total body fat and distribution</outcome>
      <timepoint>Change at follow up compared to 6 years ago</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in fasting insulin, c-peptide, glucose levels</outcome>
      <timepoint>Change at follow up compared to 6 years ago</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in HbA1c, 75g oral glucose tolerance</outcome>
      <timepoint>Change at follow up compared to 6 years ago</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in fasting non-esterified fatty acids and lipids profile</outcome>
      <timepoint>Change at follow up compared to 6 years ago</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in circulating adipokines, cytokines and hepatokines</outcome>
      <timepoint>Change at follow up compared to 6 years ago</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in blood pressure</outcome>
      <timepoint>Change at follow up compared to 6 years ago</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Participation in the previous SiDIRAD (1) or EXCESS (2-6) study.

          -  Willingness to give written informed consent and willingness to participate in and
             comply with the study.</inclusivecriteria>
    <inclusiveminage>26</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>75</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>-  Pregnant and/or lactating women.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Other</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>1/11/2013</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>68</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/02/2016</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW</recruitmentstate>
    <hospital>Garvan Institute of Medical Research - Darlinghurst</hospital>
    <postcode>2010 - Darlinghurst</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Garvan Institute of Medical Research</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Baker IDI Heart and Diabetes Institute</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Chinese University of Hong Kong</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Diabetes Australia</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>People who are overweight and/or obese usually are insulin resistant and so are at risk of
      type 2 diabetes. However, research has shown that some overweight and/or obese people remain
      insulin sensitive and healthy despite their weight.

      The investigators hypothesise that insulin-sensitive overweight and/or obese people maintain
      their insulin sensitivity and metabolic health over time. The investigators also hypothesise
      that the preservation of insulin sensitivity will be determined by key metabolic factors.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02017210</trialwebsite>
    <publication>Tonks KT, Ng Y, Miller S, Coster AC, Samocha-Bonet D, Iseli TJ, Xu A, Patrick E, Yang JY, Junutula JR, Modrusan Z, Kolumam G, Stöckli J, Chisholm DJ, James DE, Greenfield JR. Impaired Akt phosphorylation in insulin-resistant human muscle is accompanied by selective and heterogeneous downstream defects. Diabetologia. 2013 Apr;56(4):875-85. doi: 10.1007/s00125-012-2811-y. Epub 2013 Jan 24.
Heilbronn LK, Campbell LV, Xu A, Samocha-Bonet D. Metabolically protective cytokines adiponectin and fibroblast growth factor-21 are increased by acute overfeeding in healthy humans. PLoS One. 2013 Oct 18;8(10):e78864. doi: 10.1371/journal.pone.0078864. eCollection 2013.
Heilbronn LK, Coster AC, Campbell LV, Greenfield JR, Lange K, Christopher MJ, Meikle PJ, Samocha-Bonet D. The effect of short-term overfeeding on serum lipids in healthy humans. Obesity (Silver Spring). 2013 Dec;21(12):E649-59. doi: 10.1002/oby.20508. Epub 2013 Jul 29.
Samocha-Bonet D, Campbell LV, Mori TA, Croft KD, Greenfield JR, Turner N, Heilbronn LK. Overfeeding reduces insulin sensitivity and increases oxidative stress, without altering markers of mitochondrial content and function in humans. PLoS One. 2012;7(5):e36320. doi: 10.1371/journal.pone.0036320. Epub 2012 May 7.
Tam CS, Viardot A, Clément K, Tordjman J, Tonks K, Greenfield JR, Campbell LV, Samocha-Bonet D, Heilbronn LK. Short-term overfeeding may induce peripheral insulin resistance without altering subcutaneous adipose tissue macrophages in humans. Diabetes. 2010 Sep;59(9):2164-70. doi: 10.2337/db10-0162. Epub 2010 Jun 14.
Samocha-Bonet D, Campbell LV, Viardot A, Freund J, Tam CS, Greenfield JR, Heilbronn LK. A family history of type 2 diabetes increases risk factors associated with overfeeding. Diabetologia. 2010 Aug;53(8):1700-8. doi: 10.1007/s00125-010-1768-y. Epub 2010 May 12.
</publication>
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Jerry R Greenfield, BSc(Med) MBBS PhD FRACP</name>
      <address>Garvan Institute of Medical Research</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>